Abstract: The present disclosure provides use of a long non-coding RNA (lncRNA) in preparation of a drug for controlling myocardial infarction, and belongs to the technical field of biomedicine. The present disclosure further provides use of a recombinant vector with a nucleic acid sequence of lncRNA CIR6 or a recombinant virus strain with the nucleic acid sequence of lncRNA CIR6 in inducing MSC differentiation into a cardiomyocytes in vitro, wherein the MSC is selected from the group consisting of a bone marrow-derived mesenchymal stem cell (BMSC) and an umbilical cord-derived mesenchymal stem cell (UCMSC). In the present disclosure, the lncRNA-CIR6 is derived from human heart. In vivo and in vitro experiments have shown that lncRNA-CIR6 induces the differentiation of the MSC into the cardiomyocyte; meanwhile, the cardiomyocyte detected by flow cytometry has an average transformation rate of not less than 90%.

Abstract: Provided is a bispecific recombinant protein, comprising a high affinity tumor-targeting arm and a low affinity fusion protein blocking the interaction of CD47 with SIRP?. The antibody corresponding to the high affinity tumor-targeting arm does not bind to CD47, and its binding affinity to the target antigen on the tumor cell is at least 6 times as great as the binding affinity of monomer fusion protein homodimer, corresponding to the low affinity fusion protein blocking the interaction of CD47 with SIRP?, to a CD47 on the tumor cell, wherein the low affinity fusion protein blocking the interaction of CD47 with SIRP? comprises a SIRP? extracellular truncation. Also provided are nucleic acid molecules encoding recombinant proteins and the use of the recombinant proteins and nucleic acid molecules in the manufacture of a medicament for treating tumors.

Abstract: Provided is a bispecific recombinant protein, comprising a high affinity tumor-targeting arm and a low affinity fusion protein blocking the interaction of CD47 with SIRP?. The antibody corresponding to the high affinity tumor-targeting arm does not bind to CD47, and its binding affinity to the target antigen on the tumor cell is at least 6 times as great as the binding affinity of monomer fusion protein homodimer corresponding to the low affinity fusion protein blocking the interaction of CD47 with SIRP?, to a CD47 on the tumor cell, wherein the low affinity fusion protein blocking the interaction of CD47 with SIRP? comprises a SIRP? extracellular truncation. Also provided are nucleic acid molecules encoding recombinant proteins and the use of the recombinant proteins and nucleic acid molecules in the manufacture of a medicament for treating tumors.

Abstract: Provided is a bispecific recombinant protein, comprising a high affinity tumor-targeting arm and a low affinity fusion protein blocking the interaction of CD47 with SIRP?. The antibody corresponding to the high affinity tumor-targeting arm does not bind to CD47, and its binding affinity to the target antigen on the tumor cell is at least 6 times as great as the binding affinity of monomer fusion protein homodimer corresponding to the low affinity fusion protein blocking the interaction of CD47 with SIRP?, to a CD47 on the tumor cell, wherein the low affinity fusion protein blocking the interaction of CD47 with SIRP? comprises a SIRP? extracellular truncation. Also provided are nucleic acid molecules encoding recombinant proteins and the use of the recombinant proteins and nucleic acid molecules in the manufacture of a medicament for treating tumors.